Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
Talaris Therapeutics (TALS), a late-stage cell therapy company, announced plans to hold a conference call on June 8, 2022, at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talaris Therapeutics (TALS), a late-stage cell therapy company, announced plans to hold a conference call on June 8, 2022, at 8:00 a.m. ET. This call will provide updates on their presentations at the American Transplant Congress and data from the ongoing Phase 3 FREEDOM-1 study focused on living donor kidney transplant recipients. Investors can join via phone or webcast through Talaris’ website.
The company is dedicated to transforming care for solid organ transplants and severe immune disorders.
Positive
- Upcoming conference call to discuss significant data updates from the Phase 3 FREEDOM-1 study.
- Focus on living donor kidney transplant, indicating strong potential for market impact.
Negative
- None.
Details
News Market Reaction – TALS
The recorded move for TALS in the trading session of this news was +1.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.
The conference call will be held on June 8, 2022 at 8:00 a.m. ET. To access the conference call, the dial-in numbers are 1-855-605-1739 for domestic callers and 1-914-987-7955 for international callers. The conference ID number for the live call will be 9988627. A live webcast of the conference call will also be available under "News & Events" in the Investors section of the Company's website at www.talaristx.com.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783
Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
(339) 970-2843
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.